This manuscript summarized one section out of the international symposium, Pancreatic Cancer 2012, which was held last October 4th through 6th in Kyoto (Japan) under the theme, "We are the Team: Opening the Door to the Next
INTRODUCTION
Vascualar reconstruction during pancreatoduodenectomy for ductal adenocarcinoma of the pancreas improves resectablility but does not achieve patients cure to Group B (2.8%, and 0%) and Group C (both 0%).
Combined vascular resection and the presence of metastatic lymph node were determined to be independent prognostic factor on multivariate analysis, indicating that PD with vascular resection increased local resectability without additional perioperative morbidity and mortality, but was not associated with improved oncologic outcome.
Especially, he claimed arterial resection should be regarded as contraindication due to high morbidity and poor survival outcome.
The result of that study are based on retrospective data collected during long-term follow-up period, and preoperative resectability was not exactly described in this study, however, it is thought that a significant portion of patients in Group B and C might had BRPC when consid- (3) there is a general lack of stated criteria for resection after neoadjuvant therapy in most studies. All of these factors make it difficult to draw a meaningful conclusion about the therapeutic role of neoadjuvnat therapy in treating pancreatic cancer.
In addition, there are various types of intervention as neoadjuvant therapy, such as different radiotherapy techniques, chemotherapeutic agents, and treatment dose/schedule.
The speaker specifically emphasized the fact that the role of radiotherapy in treating pancreatic cancer is still controversial. Considering the recurrence pattern of pancreatic cancer after both local radiotherapy and systemic therapy, he suggested chemotherapy would be ideal in treating pancreatic cancer. In fact, the addition of radiotherapy in an adjuvant setting was reported to decrease the local recurrence rate as low as 10%. [6] [7] [8] [9] However, several randomized prospective study showed conflicting results, and no large randomized controlled study had been conducted on the use of neoadjuvant therapy in resectable pancreatic cancer. He concluded by reiterating that the routine use of neoadjuvant radiotherapy or chemoradiation therapy in treating pancreatic cancer remains controversial.
10
Call for a standard set of definitions for BRPC Role of the medical oncologist, criteria for down staging, role of CT imaging, success rates for resection, and survival results Various preoperative regimens, possibly including radiation therapy, also should be tested in BRPC. In addition, most recent developed agents need to be tested in un- level. This group recently reviewed 135 consecutive patients treated with neoCRT followed by pancreatectomy for pancreatic cancer. 16 Pathologic response was defined as minor (＜50% fibrosis relative to residual neoplastic cells), partial (50-94% fibrosis), or major (95%≤fibrosis). The currently available grading system used to assess the treatment effect of neoadjuvant therapy in pancreatic cancer is summarized ( Table 1) . The Mie University Experinece: Chemoradiotherapy followed by surgery for pancreatic ductal adenocarcinoma: ShujiIsalji from Mie University (Japan) 5. Recently, many institutions have adopted pancreatectomy followed by neoadjuvant therapy for advanced pancreatic cancer.
In addition, it is thought that more evidence-based standardization of definition for BRPC, neoadjuvnat therapy protocol, operative records, and pathologic examination for histologic response is required to adequately address the role of pancreatectomy followed by neoadjuvnat therapy in treating BRPC.
